Myriad - Vectra Testing Business
- Company typePublic
- Founded1991
- HeadquartersSalt Lake City, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
Myriad - Vectra Testing Business firmographics
Firmographics- Name
- Myriad - Vectra Testing Business
- Legal name
- Myriad Genetics, Inc.
- Website
- https://myriad.com
- Company type
- Public
- Founded year
- 1991
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
Myriad - Vectra Testing Business industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)
- akta.pro secondary industries
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling) (HLAAAMAK)
Keywords
Where Myriad - Vectra Testing Business is headquartered
LocationHeadquarters
- HQ city
- Salt Lake City
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Myriad - Vectra Testing Business business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Genetic Testing Services: Myriad generates revenue through one-time genetic test fees billed to commercial insurance plans, Medicare, Medicaid, and directly to patients. The majority of patients face no out-of-pocket costs due to insurance coverage. Patients without coverage or with high deductibles can opt for fixed-price direct payment. The company also offers financial assistance programs for eligible patients.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Prenatal screen financial assistance tiers |
| One time/ perpetual license | Pay-as-you-go | Myriad Financial Assistance Program income-based tiers |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Myriad - Vectra Testing Business product offering
Product offeringCore offering
Myriad operates a clinical molecular diagnostic laboratory that provides genetic and genomic testing services across hereditary cancer risk, oncology tumor profiling, prenatal/reproductive health, and mental health pharmacogenomics. Within the Vectra Testing Business, Myriad offers Vectra, a non-invasive, blood-based multi-biomarker disease activity test for rheumatoid arthritis, alongside its broader portfolio of FDA-approved companion diagnostics (BRACAnalysis CDx, MyChoice CDx), somatic tumor profiling (Precise Tumor), MRD monitoring (Precise MRD), and AI-enhanced prostate cancer testing (Prolaris + AI). Tests are ordered primarily by healthcare providers through a dedicated Provider Portal, with sample collection supported by a nationwide network of partner labs and mobile phlebotomy services.
Product overview
Myriad Genetics offers a comprehensive portfolio of molecular diagnostic tests organized across five health areas: hereditary cancer risk (MyRisk with RiskScore, BRACAnalysis CDx, MyChoice CDx), oncology (Precise Tumor, Precise MRD, Prolaris+AI), reproductive health/prenatal care (Foresight Carrier Screen, Prequel NIPT with AMPLIFY technology, SneakPeek, FirstGene), and mental health (GeneSight pharmacogenomics). The flagship MyRisk test evaluates 63 genes for 11 hereditary cancers and includes the proprietary RiskScore polygenic breast cancer risk assessment. The product portfolio includes FDA-approved companion diagnostics (BRACAnalysis CDx, MyChoice CDx), somatic tumor profiling (Precise Tumor), MRD monitoring (Precise MRD), and AI-enhanced genomic tests (Prolaris+AI). Prenatal offerings include carrier screening and NIPT with industry-leading detection rates and lowest failure rates. The company provides tests via healthcare providers with supporting services including genetic counseling, financial assistance programs, and provider portals.
Differentiator
Problem solved
Functional benefit
Brands
- Myriad Oncology: Oncology division offering genetic testing for cancer treatment including germline and tumor genomic testing
- Myriad Women's Health
- GeneSight
- Myriad Urology
Products and services
- Vectra A non-invasive, blood-based test that analyzes 12 biomarkers to measure rheumatoid arthritis (RA) disease activity, providing clinicians an objective assessment of RA disease status to guide treatment decisions.
- MyRisk Hereditary Cancer Test A comprehensive germline hereditary cancer test evaluating 63 genes associated with 11 hereditary cancers, including the RiskScore feature that provides personalized 5-year and lifetime breast cancer risk estimates.
- BRACAnalysis CDx FDA-approved germline companion diagnostic test for patients with breast, ovarian, pancreatic, and prostate cancer that identifies BRCA1/2 mutations to inform treatment decisions.
- MyChoice CDx The most comprehensive FDA-approved tumor test that determines HRD (Homologous Recombination Deficiency) status in women with ovarian cancer to inform PARP inhibitor treatment strategies.
- Precise Tumor Somatic tumor testing that assesses 500+ genes and key biomarkers including MSI, TMB, and PD-L1 to identify actionable genomic variants and guide targeted therapy selection.
- Precise MRD Ultrasensitive whole-genome sequencing test for molecular residual disease (MRD) monitoring, providing personalized molecular tracking throughout cancer patient journeys.
- Prolaris + AI AI-enhanced cell-cycle proliferation-based biomarker test for untreated men with prostate cancer that determines tumor aggressiveness, growth rate, and recurrence risk to guide treatment decisions.
- Foresight Carrier Screen Genetic carrier screening test identifying at-risk couples for passed inherited conditions with >99% detection rate across ancestries, screening for serious actionable conditions.
- Prequel Prenatal Screen Non-invasive prenatal testing (NIPT) using cell-free DNA to screen for chromosomal conditions like Down, Edwards, Patau, and DiGeorge syndromes as early as week 8 of pregnancy, with AMPLIFY fetal fraction amplification.
- SneakPeek Early Gender Test Fetal sex determination test identifying baby gender as early as six weeks into pregnancy using cell-free DNA analysis.
- FirstGene Multiple Prenatal Screen Next-generation prenatal screening providing actionable genetic insights via simple blood draw as early as 10 weeks gestation.
- GeneSight Pharmacogenomic test leveraging genetics to help clinicians understand how patient metabolism may impact response to antidepressants and other mental health medications.
Quantifiable outcome
- RiskScore is twice as accurate as Tyrer-Cuzick breast cancer risk assessment alone
- +3 more outcomes
Companies that use Myriad - Vectra Testing Business
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Myriad - Vectra Testing Business technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Myriad - Vectra Testing Business partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- DNAvisitcoreDNAvisit is Myriad's virtual care partner offering hereditary cancer testing through at-home saliva kits. Patients receive virtual guidance from board-certified genetic counselors, enabling access to MyRisk testing from home without needing an in-person office visit.
- Phleb-FindersminorMobile phlebotomy partner providing at-home blood draw services for Myriad patients nationwide. Myriad covers the cost of blood draw when patients choose partnered mobile phlebotomy services.
- TravaLabminorMobile phlebotomy partner providing at-home blood draw services for Myriad patients nationwide. Myriad covers the cost of blood draw when patients choose partnered mobile phlebotomy services.
- GetlabsminorMobile phlebotomy partner providing at-home blood draw services for Myriad patients nationwide. Myriad covers the cost of blood draw when patients choose partnered mobile phlebotomy services.
- Any Lab Test NowminorRetail blood draw partner offering walk-in or appointment-based phlebotomy services for Myriad test samples at multiple locations across the US.
- Clinical Pathology Laboratories (CPL)minorLaboratory partner providing blood draw services for Myriad test sample collection at multiple clinic locations across the US.
- PathGroupminorLaboratory partner providing blood draw services for Myriad test sample collection at multiple clinic locations across the US.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Myriad - Vectra Testing Business competitors and assessment
Company assessmentBroad incumbents
- Quest Diagnostics: Broad incumbent clinical laboratory providing genetic and molecular diagnostic services across reproductive health, oncology, and rare disease. Quest overlaps with Myriad across most product lines and competes on national blood draw infrastructure and payer contracts.
- Foundation Medicine: Broad incumbent in comprehensive genomic profiling (FoundationOne CDx, FoundationOne Liquid CDx) within oncology. Owned by Roche, Foundation competes with Myriad's somatic and companion diagnostic franchises as part of a much larger oncology portfolio.
- Laboratory Corporation of America (Labcorp): Broad incumbent clinical laboratory offering routine and esoteric testing including NIPT, hereditary cancer, and oncology services. Labcorp competes with Myriad across multiple categories via its own lab operations and acquired specialty labs.
- Exact Sciences: Broad incumbent in cancer diagnostics (Cologuard, Oncotype DX, TheraTrack) with overlapping presence in oncology testing. While Exact Sciences is strongest in colorectal screening, its oncology portfolio competes with Myriad's tumor profiling and hereditary cancer franchises.
Direct peers
- Guardant Health: Direct peer in liquid biopsy and tumor profiling (Guardant360) and an emerging MRD player. Guardant competes with Myriad's Precise Tumor and Precise MRD franchises and overlaps on biopharma companion diagnostic partnerships.
- Caris Life Sciences: Direct peer in tumor profiling and molecular oncology, with a broad biomarker panel (MI Profile) overlapping Myriad's Precise Tumor and Prolaris offerings. Both target oncologists and biopharma with comprehensive tumor profiling services.
- Natera: Direct peer across hereditary cancer testing (Empower), NIPT (Panorama), and MRD monitoring (Signatera). Natera competes head-to-head with Myriad in oncology, reproductive health, and MRD — many of Myriad's core growth bets directly counter Natera's franchises.
- Invitae: Direct peer in hereditary cancer and broad germline genetic testing, with comparable panel structure to MyRisk. Invitae competes on the same provider ordering motion across oncology, reproductive health, and pharmacogenomics.
- NeoGenomics: Direct peer in oncology-focused molecular diagnostics including tumor profiling and hematology testing. NeoGenomics competes with Myriad's oncology division across hospital and community oncology channels.
Emerging players
- Tempus: Emerging AI-driven precision medicine player in oncology and neuropsychiatry with xT, xR, and xG tests. Tempus overlaps with Myriad in tumor profiling, MRD, and pharmacogenomics (particularly GeneSight), and represents a fast-moving AI-native competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Myriad - Vectra Testing Business social profiles
Digital presenceMyriad - Vectra Testing Business financial estimates
Financial estimateRevenue estimate
Valuation estimate
Myriad - Vectra Testing Business leadership team
Management profileNumber of profiles
Profiles5 records
Myriad - Vectra Testing Business funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Myriad - Vectra Testing Business M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Myriad - Vectra Testing Business
What does Myriad - Vectra Testing Business do?
Myriad operates a clinical molecular diagnostic laboratory that provides genetic and genomic testing services across hereditary cancer risk, oncology tumor profiling, prenatal/reproductive health, and mental health pharmacogenomics. Within the Vectra Testing Business, Myriad offers Vectra, a non-invasive, blood-based multi-biomarker disease activity test for rheumatoid arthritis, alongside its broader portfolio of FDA-approved companion diagnostics (BRACAnalysis CDx, MyChoice CDx), somatic tumor profiling (Precise Tumor), MRD monitoring (Precise MRD), and AI-enhanced prostate cancer testing (Prolaris + AI). Tests are ordered primarily by healthcare providers through a dedicated Provider Portal, with sample collection supported by a nationwide network of partner labs and mobile phlebotomy services.
Is Myriad - Vectra Testing Business a public or private company?
Myriad - Vectra Testing Business is a public company. It is classified as public and is currently operating.
When was Myriad - Vectra Testing Business founded?
Myriad - Vectra Testing Business was founded in 1991. It employs 1,001 to 5,000 people.
Where is Myriad - Vectra Testing Business based?
Myriad - Vectra Testing Business is headquartered in Salt Lake City, United States, in the North America region.
How does Myriad - Vectra Testing Business make money?
One revenue line is on record: genetic Testing Services.
Who are Myriad - Vectra Testing Business's main competitors?
Broad incumbents on record are Quest Diagnostics, Foundation Medicine, Laboratory Corporation of America (Labcorp) and Exact Sciences. Direct peers are Guardant Health, Caris Life Sciences, Natera, Invitae and NeoGenomics. Tempus is listed as an emerging player.
Does Myriad - Vectra Testing Business have an API?
No public API is recorded for Myriad - Vectra Testing Business.
What industry is Myriad - Vectra Testing Business in?
Myriad - Vectra Testing Business's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 6215 and its SIC code is 8071.